Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Elafibranor in Healthy Adults
NCT05564208Phase 1Completed
- Sponsor
- Ipsen
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elafibranor in primary biliary cholangitis (PBC) (2 arms), sponsored by Ipsen. Primary endpoints: Area Under the Plasma Concentration Time Curve From Zero to Last Quantifiable Concentration, Area Under Plasma Concentration Time Curve From Zero to Infinity and 1 more. Started Oct 2022; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05564208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564208.